TRVI Stock Forecast & Price Target

Trevi Therapeutics Inc demonstrates a positive outlook due to increased projected sales for Haduvio across indications, supported by strong data revealing low-dose and rapid efficacy which enhances market penetration despite its positioning as a second-line to third-line treatment option. The results from the RIVER RCC trial showed significant improvements in responder rates, alongside supportive patient-reported outcomes that align with primary measures, indicating a robust clinical profile for Haduvio. Furthermore, projected peak sales for Haduvio have been raised to $1.7 billion, reflecting improved net pricing and patient penetration rates, while potential revenue from international markets and additional indications remains a significant upside to the company's financial model.

Trevi Therapeutics Inc. faces a negative outlook as it is projected to incur significant and escalating operating expenses related to the clinical development of Haduvio, with cash burn anticipated until at least 2029 before any product launch. The company's long timeline to commercial viability, coupled with the need for additional financing to reach breakeven, raises concerns about its financial stability and ability to sustain operations. Furthermore, comparatives with competitors' efficacy results indicate that Trevi's prospects may be less favorable, compounding the challenges the company faces in achieving market success.